These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 37846840)

  • 1. Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine.
    Li W; Zhao T; Tao B; Zhao L; Xiao H; Ding X; Li C; Chen L; Cheng H; Lou Y; Chen Y; Wu C
    Hum Vaccin Immunother; 2023 Aug; 19(2):2264589. PubMed ID: 37846840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants.
    Fryer HA; Geers D; Gommers L; Zaeck LM; Tan NH; Jones-Freeman B; Goorhuis A; Postma DF; Visser LG; Hogarth PM; Koopmans MPG; GeurtsvanKessel CH; O'Hehir RE; van der Kuy PHM; de Vries RD; van Zelm MC
    J Infect; 2024 Oct; 89(4):106246. PubMed ID: 39127451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants.
    Li H; Yang C; Yin L; Liu W; Zhang Z; Liu B; Sun X; Liu W; Lin Z; Liu Z; He P; Feng Y; Wang C; Wang W; Guan S; Wang Q; Chen L; Li P
    Emerg Microbes Infect; 2024 Dec; 13(1):2387447. PubMed ID: 39082740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model.
    Ji Y; Sui X; Miao W; Wang C; Wang Q; Duan Z; Wei B; Wu D; Wei M; Shao J; Zheng X; Zhu T
    Vaccine; 2024 Feb; 42(6):1292-1299. PubMed ID: 38296705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.
    Canaday DH; Oyebanji OA; White EM; Bosch J; Nugent C; Vishnepolskiy I; Abul Y; Didion EM; Paxitzis A; Sundheimer N; Ragavapuram V; Wilk D; Keresztesy D; Cao Y; St Denis K; McConeghy KW; McDonald LC; Jernigan JA; Mylonakis E; Wilson BM; King CL; Balazs AB; Gravenstein S
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(4):100-106. PubMed ID: 36701254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
    Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K
    Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants.
    Wang R; Huang H; Yu C; Sun C; Ma J; Kong D; Lin Y; Zhao D; Zhou S; Lu J; Cao S; Zhang Y; Luo C; Li X; Wang Y; Xie L
    Sci China Life Sci; 2023 Aug; 66(8):1818-1830. PubMed ID: 36598621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine.
    Wang Q; Guo Y; Tam AR; Valdez R; Gordon A; Liu L; Ho DD
    Cell Rep Med; 2023 Nov; 4(11):101258. PubMed ID: 37909042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.
    Scheaffer SM; Lee D; Whitener B; Ying B; Wu K; Liang CY; Jani H; Martin P; Amato NJ; Avena LE; Berrueta DM; Schmidt SD; O'Dell S; Nasir A; Chuang GY; Stewart-Jones G; Koup RA; Doria-Rose NA; Carfi A; Elbashir SM; Thackray LB; Edwards DK; Diamond MS
    Nat Med; 2023 Jan; 29(1):247-257. PubMed ID: 36265510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of Monovalent mRNA-1273 and BNT162b2 Vaccines in Children <5 Years of Age.
    Dalapati T; Williams CA; Giorgi EE; Hurst JH; Herbek S; Chen JL; Kosman C; Rotta AT; Turner NA; Pulido N; Aquino JN; Pfeiffer TS; Rodriguez J; Fouda GG; Permar SR; Kelly MS
    Pediatrics; 2024 Jun; 153(6):. PubMed ID: 38548700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.
    Zang J; Yin Y; Xu S; Qiao W; Liu Q; Lavillette D; Zhang C; Wang H; Huang Z
    Front Immunol; 2022; 13():908478. PubMed ID: 35844601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial.
    Branche AR; Rouphael NG; Diemert DJ; Falsey AR; Losada C; Baden LR; Frey SE; Whitaker JA; Little SJ; Anderson EJ; Walter EB; Novak RM; Rupp R; Jackson LA; Babu TM; Kottkamp AC; Luetkemeyer AF; Immergluck LC; Presti RM; Bäcker M; Winokur PL; Mahgoub SM; Goepfert PA; Fusco DN; Malkin E; Bethony JM; Walsh EE; Graciaa DS; Samaha H; Sherman AC; Walsh SR; Abate G; Oikonomopoulou Z; El Sahly HM; Martin TCS; Kamidani S; Smith MJ; Ladner BG; Porterfield L; Dunstan M; Wald A; Davis T; Atmar RL; Mulligan MJ; Lyke KE; Posavad CM; Meagher MA; Stephens DS; Neuzil KM; Abebe K; Hill H; Albert J; Telu K; Mu J; Lewis TC; Giebeig LA; Eaton A; Netzl A; Wilks SH; Türeli S; Makhene M; Crandon S; Montefiori DC; Makowski M; Smith DJ; Nayak SU; Roberts PC; Beigel JH;
    Nat Med; 2023 Sep; 29(9):2334-2346. PubMed ID: 37640860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omicron Variant-Specific Serological Imprinting Following BA.1 or BA.4/5 Bivalent Vaccination and Previous SARS-CoV-2 Infection: A Cohort Study.
    Baerends EAM; Reekie J; Andreasen SR; Stærke NB; Raben D; Nielsen H; Petersen KT; Johansen IS; Lindvig SO; Madsen LW; Wiese L; Iversen MB; Benfield T; Iversen KK; Larsen FD; Andersen SD; Juhl AK; Dietz LL; Hvidt AK; Ostrowski SR; Krause TG; Østergaard L; Søgaard OS; Lundgren J; Tolstrup M
    Clin Infect Dis; 2023 Nov; 77(11):1511-1520. PubMed ID: 37392436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5.
    Kawasuji H; Morinaga Y; Tani H; Saga Y; Yamada H; Yoshida Y; Takegoshi Y; Kaneda M; Murai Y; Kimoto K; Ueno A; Miyajima Y; Nagaoka K; Ono C; Matsuura Y; Niimi H; Yamamoto Y
    Microbiol Spectr; 2023 Mar; 11(2):e0513122. PubMed ID: 36946738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibody response after immunization with a COVID-19 bivalent vaccine: Insights to the future.
    Souza MS; Farias JP; Andreata-Santos R; Silva MP; Brito RDDS; Duarte Barbosa da Silva M; Peter CM; Cirilo MVF; Luiz WB; Birbrair A; Vidal PO; de Castro-Amarante MF; Candido ED; Munhoz AS; de Mello Malta F; Dorlass EG; Machado RRG; Pinho JRR; Oliveira DBL; Durigon EL; Maricato JT; Braconi CT; Ferreira LCS; Janini LMR; Amorim JH
    J Med Virol; 2024 Feb; 96(2):e29416. PubMed ID: 38285457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years.
    Winokur P; Gayed J; Fitz-Patrick D; Thomas SJ; Diya O; Lockhart S; Xu X; Zhang Y; Bangad V; Schwartz HI; Denham D; Cardona JF; Usdan L; Ginis J; Mensa FJ; Zou J; Xie X; Shi PY; Lu C; Buitrago S; Scully IL; Cooper D; Koury K; Jansen KU; Türeci Ö; Şahin U; Swanson KA; Gruber WC; Kitchin N;
    N Engl J Med; 2023 Jan; 388(3):214-227. PubMed ID: 36652353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bivalent Coronavirus Disease 2019 Vaccine Antibody Responses to Omicron Variants Suggest That Responses to Divergent Variants Would Be Improved With Matched Vaccine Antigens.
    Wang W; Goguet E; Paz S; Vassell R; Pollett S; Mitre E; Weiss CD
    J Infect Dis; 2023 Aug; 228(4):439-443. PubMed ID: 37279924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.